Психотерапия изменяет работу мозга на химическом уровне - Научные исследования - Каталог статей - Семейный психолог, психотерапевт, Ростов-на-Дону.
Пятница, 26.03.2010, 05:05
Главная Регистрация Вход
Приветствую Вас, Гость · RSS
Меню сайта
Категории раздела
Теория психотерапии [3]
Практика психотерапии [2]
Научные исследования [1]
Семейная система [0]
Altera [0]
Форма входа
 Каталог статей
Главная » Статьи » Научные исследования

Психотерапия изменяет работу мозга на химическом уровне

Биоимия психотерапевтического процесса

August 12, 2008

Nature or Nurture - Are You Who Your Brain Chemistry Says You Are?

A First-of-Its-Kind PET Study Reveals Direct Link Between Hereditary Personality Trait and Brain's Endorphine System, According to an Article in The Journal of Nuclear Medicine

Reston, Va.—Researchers using positron emission tomography (PET) have validated a long-held theory that individual personality traits—particularly reward dependency—are connected to brain chemistry, a finding that has implications for better understanding and treating substance abuse and other addictive behaviors.

In a study to identify biochemical correlates of personality traits in healthy humans, researchers focused their investigation for the first time on the role of the brain's opioidergic (or endorphine) system—specifically, the connection between an individual's level of reward expectancy and the brain's ability to transmit naturally occurring opiates. The study included 23 males with no history of substance abuse who were administered Fluoro-ethyl-diprenorphine—a radiolabeled chemical that binds readily to the brain's naturally occurring opiate system— and then underwent a PET scan.

The scans were compared to the results of each participant's Cloninger temperament and character inventory, a questionnaire that assesses human personality based on four dimensions: novelty seeking, harm avoidance, reward dependence and persistence. The comparison revealed that the binding to opiate receptors in the ventral striatum—an area of the brain known to be a central part of the reward system—correlated narrowly to the individual degree of reward dependence. The participants who skewed toward a high need to feel rewarded by approval were also those with the highest uptake of opiates, or endorphins, in the reward system.
"Our main finding was that reward dependence is the only personality dimension correlated with opiate receptor binding, and that positive correlation was restricted to the ventral striatum, which is considered the key area of the human reward system and of the development of addictive behavior," said Peter Bartenstein, M.D., professor of nuclear medicine, Ludwig Maximilians-University, Munich, Germany. "This correlation means that people with high reward dependence have a high concentration of opiate receptors available in that area, while people with low dependence have fewer opiate receptors."

According to the researchers, the biological purpose of the human reward system is to initiate behavior essential for the maintenance of the individual—for example, food intake—or the species—for example, reproduction. Therefore, food or sexual stimuli lead to an opioid-modulated dopamine release in core structures of the reward system and subsequently induce the sensation of craving. Modern addiction research maintains that genetic or acquired abuses of the reward system are the central basis for the development of addictive behavior. This latest finding suggests that individuals suffering from a relative endorphine deficit in their reward system show increased reward dependence and are probably more at risk for developing addictions.
"This is a novel finding and will provide a deeper understanding of the functional relation between human personality, neurobiology and addictive behavior," said Mathias Schreckenberger, M.D., professor of nuclear medicine, Johannes Gutenberg-University, Mainz, Germany. "Understanding the central role of neurotransmission processes in certain brain structures for the expression of psychologically defined constructs such as personality will make a great difference in the future of medicine."

The researchers foresee PET becoming the preferred imaging method for individualized therapy in a range of disorders caused by addictive behaviour—such as drug abuse or pathological gambling—because it is the only method able to show specific local changes in different neurotransmitter systems (opiate, dopamine and serotonine) involved in addiction. These changes are different in different people and different types of addiction.

The researchers further suggest that PET could be used to predict a favorable response to treatment with drugs that block agents such as morphine, heroin or alcohol from binding to opiate receptors and may one day aid in determining treatment of other psychiatric diseases, such as personality disorders. PET may also play a central role in the development and preclinical evaluation of new anti-craving drugs since it enables researchers to investigate noninvasively the in vivo pharmacological effects of these drugs on the reward system.

The group's next study will delve deeper into the description of the neurochemistry of human personality and expand study sample sizes, according to Gerhard Gründer, M.D., professor of psychiatry and psychotherapy, Aachen University, Aachen, Germany.
"One of the more interesting aspects of this study," he added, "is that it shows that PET technology is capable of detecting subtle biochemical differences in the brain in healthy persons, which may ultimately be responsible for what we consider the individual personality. This has far-reaching implications—not only for choosing the best individual treatments, but also in discussions of an individual's free will."

Coauthors of "Opiod Receptor PET Reveals the Psycholobiologic Correlates of Reward Processing" include Mathias Schreckenberger, Peter Bartenstein, André Klega, Hans-Georg Buchholz, Christina Müller, department of nuclear medicine, and Armin Scheurich, department of psychiatry and psychoterapy, all at Johannes Gutenberg-University, Mainz, Germany; Gerhard Gründer, department of Psychiatry and Psychotherapy, Aachen University, Aachen, Germany; Ralf Schirrmacher, Esther Schirrmacher, department of neurology and neurosurgery , McGill University, Montreal, Canada; Gjermund Henriksen, department of nuclear medicine, Technical University, Munich, Germany.

Credentialed media: To obtain a copy of this article—and online access to The Journal of Nuclear Medicine— please contact Amy Shaw by phone at (703) 652-6773 or email ashaw@snm.org. Current and past issues of the Journal of Nuclear Medicine can be found online at jnm.snmjournals.org. A subscription to the journal is an SNM member benefit.

About SNM
SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.
SNM's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice.
For more information, visit www.snm.org.

Источник: http://interactive.snm.org/index.cfm?PageID=7929&RPID=969
Категория: Научные исследования | Добавил: Сергей (05.06.2009) | Автор: Сергей Михайлов
Просмотров: 130 | Теги: опиаты, опиоидные рецепторы, биохимия, психофизиология, булимия, психотерапия | Рейтинг: 0.0/0
Всего комментариев: 0
Добавлять комментарии могут только зарегистрированные пользователи.
[ Регистрация | Вход ]
Copyright CCC "Совет@Любовь!" © 2010
Rambler's Top100